Paddler, I do not see what is wrong with having a great candidate like Z160 combined with Z944 for breakthrough pain. Lets face it, Z944 cannot stand on its own. Patients will demand opioid based drugs. Z944 has to re-enter trials for seizures or cancer, so forget about these. Justin said the treasure is going to Z160 and sodium channels. Listen to his talk again, and you tell me where the cash is going to come from to support Z944. Now, we have learned that Z944 will be delayed as thought leaders figure it out. You are a thought leader. Would you combine Z160+Z944? YES! Trust me Paddler, this is where this is going. And, it is ok. It is ok and good news. This is Z160 2.0 next generation. Relax and enjoy the increased bioavailability and patent protection and Z160 news pending.